-
Cefiderocol Activity in Resistant European Non-Fermenters
2026-09-13
This multicountry study compared cefiderocol with β-lactam/β-lactamase inhibitor combinations against European Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and newer combination therapies. Its isolate-level susceptibility and resistance-mechanism data support parallel early testing when therapeutic options for non-fermenting Gram-negative infections are limited.
-
Cefiderocol Activity in Resistant European Enterobacterales
2026-09-12
This European surveillance study compared cefiderocol with approved and developmental β-lactam/β-lactamase inhibitor combinations across 1,909 Enterobacterales isolates, including difficult-to-treat resistant phenotypes. Its large, resistance-mechanism-informed design showed high cefiderocol in vitro susceptibility while also identifying iron-uptake, carbapenemase, and ftsI-associated features of cefiderocol resistance.
-
ATP Solution (100 mM): Reliable Assay Workflows
2026-09-12
A scenario-based guide to using ATP Solution (100 mM), SKU K1043, in kinase, transcription, ligation, phosphorylation, and ATP-linked cell assays. It separates reagent control from biological interpretation and provides practical dilution, storage, compatibility, and vendor-selection guidance.
-
Faropenem Sodium: From Penem to Transport
2026-09-11
Faropenem sodium is more than a broad-spectrum penem antibiotic: it is a useful translational probe linking PBP-driven bacterial killing with epithelial transporter biology. This article outlines how to design better antimicrobial, resistance, and disposition studies while distinguishing established evidence from testable hypotheses.
-
Meropenem Research in the Carbapenem Resistance Era
2026-09-11
Meropenem remains a powerful mechanistic and translational tool for studying bacterial cell-wall inhibition, infection biology, and carbapenem resistance. This article connects PBP pharmacology with recent evidence on plasmid-associated carbapenemase transmission and proposes a research strategy that evaluates antibacterial response alongside resistance mobility.
-
Cefepime (BMY-28142) in Infection Research
2026-09-10
Cefepime (BMY-28142) is a broad-spectrum cephalosporin research compound that inhibits bacterial cell-wall synthesis. Its value as a bacterial infection model comparator is strongest when antimicrobial activity, resistance genotype, CNS exposure, and neurotoxicity boundaries are evaluated separately.
-
Gepotidacin for Uncomplicated Gonorrhea: Phase 2 Evidence
2026-09-10
This phase 2 randomized study evaluated whether a single oral dose of gepotidacin could eradicate uncomplicated urogenital Neisseria gonorrhoeae infection. Both 1500-mg and 3000-mg doses produced at least 95% microbiological eradication in the microbiologically evaluable population, while treatment failures were associated with a common mutation and the highest observed gepotidacin MIC.
-
Sodium dicloxacillin monohydrate for MSSA Assays
2026-09-09
Build more informative MSSA experiments with a PBP-directed β-lactam benchmark that supports extracellular, intracellular, pH-stratified, and analytical workflows. This guide connects practical assay design with spectrophotometric quality-control insights and troubleshooting strategies.
-
Firefly Luciferase mRNA: Assay Design Guide
2026-09-09
Firefly Luciferase mRNA can function as more than a simple reporter: it can help separate delivery, translation, and immune effects in complex cell studies. This guide uses 5-moUTP chemistry and recent delivery research to develop a practical, evidence-aware assay strategy.
-
EGTA Workflows for Calcium Inflammation
2026-09-08
Use EGTA to distinguish extracellular calcium influx from downstream inflammatory signaling in endothelial, neural, and cytotoxicity assays. This practical guide combines the Talin1–Piezo1–YAP model with formulation controls, timed chelation, and troubleshooting for cleaner calcium-dependent readouts.
-
Aztreonam Workflows for Gram-Negative Research
2026-09-08
Use Aztreonam as a focused probe for Gram-negative bacterial phenotyping, while linking growth responses to resistance-gene localization and transmission experiments. The same compound also supports carefully controlled investigations of bone marrow progenitor cell inhibition and effects on liver cytochrome P450 enzymes.
-
High-Throughput Quantification of Fractional Killing
2026-09-07
Inde, Rodencal, and Dixon present a time-resolved microscopy protocol for measuring drug-induced fractional killing rather than relying only on bulk endpoint viability. The workflow combines fluorescent live-cell labeling, dead-cell detection, automated imaging, and comparative analysis to evaluate many treatment conditions in parallel, including MEK1/2 inhibitor responses.
-
Cy3 NHS Ester (Non-Sulfonated): Workflow Guide
2026-09-05
Cy3 NHS ester (non-sulfonated) provides orange fluorescence for labeling primary amino groups on proteins, peptides, and oligonucleotides. It is appropriate when DMSO or DMF is compatible with the sample, but not for strictly aqueous workflows or long-term storage of dye solutions.
-
EdU Imaging Kits (Cy3) for HCC S-Phase Studies
2026-09-05
EdU Imaging Kits (Cy3) enable denaturation-free visualization of DNA replication for hepatocellular carcinoma experiments, from NPC1 pathway studies to drug-response profiling. The workflow combines bright Cy3 labeling with preserved morphology and antigen accessibility, making it practical for fluorescence microscopy, flow cytometry, and multiparameter validation.
-
Mouse Neutrophil Cell Isolation Kit Workflow
2026-09-04
Build a rapid, column-free workflow for high-purity mouse neutrophil preparation from bone marrow, blood, or spleen. Negative selection leaves target cells unlabeled, making the preparation well suited to activation-sensitive assays, co-culture, and neutrophil-focused mRNA nanovaccine research.